BioSpace News Archive

Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it will present preclinical and early clinical data from its Phase 1/1b clinical trial of CPI-818 at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019.

Apellis Pharmaceuticals Inc. announced that on August 6, 2019, the Company approved the grant of an equity award to a new employee with a grant date of November 1, 2019 as an equity inducement award outside of the Company’s 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company.

AbbVie Inc. announced today that the requisite number of consents have been received to adopt certain proposed amendments with respect to all outstanding notes of certain series issued by Allergan Finance, LLC (“Allergan Finance”), Allergan, Inc. (“Allergan Inc”), Allergan Sales, LLC (“Allergan Sales”) and Allergan Funding SCS

Cidara Therapeutics, Inc. reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline.

IGM Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2019 and provided an update on recent developments.

Reinforces prior study results demonstrating proportional dose response and that bioavailability of CaPre is not meaningfully affected by the fat content of a meal

VolitionRx Limited (NYSE American: VNRX) (“Volition”) today announced it will host a conference call on Wednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providing a business update.

Illusio’s augmented reality platform enables cosmetic surgeons to visually display potential outcomes on a patient’s body by superimposing a 3D virtual image in real-time.

LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, announced today the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Integrated Electronics.